Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration today cautioned patients and healthcare providers against changing treatments based on results from pharmacogenetic tests with unproven indications that the agency hasn't approved for marketing.

The FDA further indicated it is looking into companies selling PGx testing for unapproved uses and may take compliance action against these firms.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.